World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-46 May 2025
ISSN: 2749-3644

CHEMOTHERAPY AND GUT MICROFLORA: A LITERATURE REVIEW ON THE EFFECTS IN MULTIPLE MYELOMA TREATMENT

J.A. Kholmatov[1], M.J. Allayeva[2], Kunal Vijay Kawale[3]
[1]Teacher-assistant of the department of Pharmacology, Tashkent medical academy, Uzbekistan
[2]Head of the department of Pharmacology, professor, Tashkent medical academy, Uzbekistan
[3]Student of International faculty, Tashkent Medical Academy, Uzbekistan
e-mail: jasurbekkholmatov01@gmail.com, juraqulovnam@gmail.com, besecialdk@gmail.com

Article history:

Received: March 30th 2025
Accepted: April 26th 2025

Abstract:

In this review, we looked at studies from 2018 to 2024 to understand how chemotherapy affects the gut microbiome in MM patients. We found that certain drugs, like melphalan and bortezomib, can significantly change the gut microbiome, making patients more likely to get infections or experience side effects. We also explored how dysbiosis can impact treatment outcomes and the cancer environment. Based on the articles we studied and discussed ways to prevent or fix these problems. For example, probiotics, special diets, and fecal microbiota transplantation (FMT) show promise in restoring a healthy gut microbiome and improving treatment results. This review highlights the importance of considering the gut microbiome in MM treatment and suggests that personalized approaches could help patients feel better and respond better to therapy. By understanding the connection between chemotherapy and the gut microbiome, we can work toward better care for MM patients.

Keywords: *Chemotherapy, Gut Microbiota, Dysbiosis, Immune System, Side Effects, Probiotics, Microbial Diversity, Therapeutic Strategies*

INTRODUCTION

Multiple myeloma (MM) is the second most common hematological malignancy, characterized by the clonal proliferation of plasma cells in the bone marrow. Despite significant advancements in treatment, including chemotherapy, proteasome inhibitors, and immunomodulatory drugs, MM remains incurable for most patients due to drug resistance and relapse. Recent research has highlighted the role of the gut microbiota in cancer progression and treatment response, particularly in hematological malignancies. The gut microbiota, comprising trillions of bacteria, fungi, viruses, and protozoa, plays a vital role in nutrient metabolism, immune regulation, and maintaining gut barrier integrity. Disruption of the gut microbiota, known as dysbiosis, has been linked to various diseases, including cancer.

Chemotherapy, a cornerstone of MM treatment, is known to cause significant alterations in the gut microbiota. These changes can lead to increased susceptibility to infections, reduced treatment efficacy, and adverse effects such as gastrointestinal toxicity. This review aims to explore the effects of chemotherapy on gut microflora in MM patients, discuss the implications of dysbiosis on treatment outcomes, and evaluate potential preventive measures, including dietary interventions, probiotics, and fecal microbiota transplantation (FMT).

MATERIALS AND METHODS

Literature Search Strategy

1. **Databases**: A systematic search was conducted using PubMed, Cochrane Library, Web of Science, and Google Scholar.
2. **Search Terms**: The following keywords were utilized: "multiple myeloma," "chemotherapy," "gut microbiota," "dysbiosis," "probiotics," "fecal microbiota transplantation," "melphalan," "bortezomib," and "immunomodulatory drugs."
3. **Inclusion Criteria**:
   - Peer-reviewed articles published between 2018 and 2024.
   - Studies focusing on human subjects or relevant preclinical models.
   - Research addressing the relationship between MM, chemotherapy, and gut microbiota.
4. **Exclusion Criteria**:
   - Non-English articles.

- Studies focusing on solid tumors without specific relevance to MM.
- Animal studies that do not provide insights applicable to human MM.

Data Extraction and Synthesis

1. Data were extracted regarding microbial taxa, chemotherapy agents, clinical outcomes, and interventions.
2. Findings were categorized into thematic sections, including effects of chemotherapy, mechanisms of dysbiosis, and preventive strategies.
3. A bias assessment was conducted, prioritizing randomized trials and longitudinal studies for clinical recommendations.

RESULTS

The Role of Gut Microbiota in Multiple Myeloma

The gut microbiota influences cancer development and treatment through various mechanisms, including modulation of the immune system, production of bioactive metabolites, and interaction with the tumor microenvironment. In MM, the gut microbiota has been shown to affect disease progression, treatment response, and the development of complications such as infections and graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation (HSCT).

Recent studies have demonstrated that MM patients exhibit significant alterations in gut microbiota composition compared to healthy individuals. These changes include reduced microbial diversity and an increased abundance of pathogenic bacteria, such as *Klebsiella pneumoniae* and *Enterobacter cloacae*, which are associated with disease progression and poor treatment outcomes [1,3]. Conversely, beneficial bacteria, such as *Eubacterium rectale* and *Faecalibacterium prausnitzii*, which produce short-chain fatty acids (SCFAs) like butyrate, have been linked to improved treatment responses and reduced inflammation [1,5].

Effects of Chemotherapy on Gut Microbiota

Chemotherapy, particularly high-dose regimens used in MM treatment, can cause significant disruptions to the gut microbiota. These disruptions are often characterized by a reduction in microbial diversity and an overgrowth of pathogenic bacteria. The mechanisms underlying chemotherapy-induced dysbiosis include direct toxicity to gut epithelial cells, alterations in gut pH, and changes in nutrient availability [1,3].

One of the most well-documented effects of chemotherapy on the gut microbiota is the reduction of SCFA-producing bacteria, such as *Clostridium butyricum* and *Eubacterium rectale*. SCFAs, particularly butyrate, play a crucial role in maintaining gut barrier integrity, regulating immune responses, and inhibiting inflammation. The loss of these beneficial bacteria can lead to increased gut permeability, systemic inflammation, and a higher risk of infections [1,5].

Chemotherapy-induced dysbiosis has also been linked to increased gastrointestinal toxicity, including mucositis, diarrhea, and nausea. These adverse effects can significantly impact patient quality of life and may lead to treatment interruptions or dose reductions, ultimately affecting treatment outcomes [1,3].

The following table (Table 1) summarizes the effects of various chemotherapy agents on gut microbiota in MM patients:

Table 1

Agent	Microbial Changes	Clinical Impact	References
Melphalan	↓ Faecalibacterium, ↑ Enterobacteriaceae	Mucositis, bacterial translocation	6
Bortezomib	↓ Lactobacillus, ↑ Clostridioides difficile	Diarrhea, reduced drug tolerance	8
Cyclophosphamide	↑ Gram-positive bacteria (e.g., *Staphylococcus*)	Increased intestinal permeability, risk of infections	9

Impact of Dysbiosis on MM Treatment Outcomes

The disruption of the gut microbiota by chemotherapy can have profound effects on MM treatment outcomes. Dysbiosis has been associated with reduced efficacy of chemotherapy and immunomodulatory drugs, increased risk of infections, and higher rates of treatment-related complications [1,3].

Several studies have shown that the gut microbiota can influence the response to proteasome inhibitors, such as bortezomib, which are commonly used in MM treatment. For example, the presence of *Eubacterium rectale* has been linked to improved treatment responses, while an overgrowth of *Klebsiella pneumoniae* has been associated with drug resistance [1,3]. Additionally, dysbiosis can impair the immune system's ability to target cancer cells, reducing the efficacy of immunotherapies such as chimeric antigen receptor (CAR) T-cell therapy [1,4].

Dysbiosis has also been linked to an increased risk of infections, particularly in MM patients undergoing HSCT. The loss of beneficial bacteria and the overgrowth of pathogenic species can lead to bacterial translocation, bloodstream infections, and sepsis. These infections can be life-threatening and may require prolonged antibiotic treatment, further exacerbating dysbiosis [1,3].

The Role of the Gut Microbiome in Plasma Cell Dyscrasias

The gut microbiome plays a crucial role in the pathogenesis and treatment of plasma cell dyscrasias, including multiple myeloma (MM). According to Jasinski et al. [9], the gut microbiota can influence the biology of plasma cell disorders through several mechanisms:

- **Microbiota Composition and Disease Progression:** Alterations in gut microbiota composition have been linked to the progression of plasma cell dyscrasias. For instance, specific bacterial populations may promote inflammation and immune dysregulation, which can contribute to the development and progression of MM. The presence of pathogenic bacteria can exacerbate the disease by enhancing systemic inflammation and impairing the immune response against malignant cells [9].
- **Impact on Treatment Efficacy:** The gut microbiome can also affect the efficacy of various treatment modalities for MM. Dysbiosis may lead to reduced effectiveness of chemotherapy and immunotherapy by altering drug metabolism and bioavailability. For example, certain gut bacteria can metabolize chemotherapeutic agents, potentially leading to decreased drug concentrations and therapeutic failure [9].
- **Immune Modulation:** The gut microbiota is integral to the regulation of the immune system. A healthy microbiome can enhance the immune response against cancer cells, while dysbiosis may impair immune function, making patients more susceptible to infections and reducing the effectiveness of immunotherapies, such as monoclonal antibodies and CAR T-cell therapy [9].
- **Clinical Implications:** Understanding the relationship between gut microbiota and plasma cell dyscrasias can lead to novel therapeutic strategies. Targeting the gut microbiome through dietary interventions, probiotics, or fecal microbiota transplantation (FMT) may enhance treatment outcomes and improve the overall management of MM patients. Future research should focus on identifying specific microbial signatures associated with treatment response and disease progression in MM [9].

Clinical Consequences of Dysbiosis

Dysbiosis resulting from chemotherapy can lead to several clinical consequences, including:

- **Increased Risk of Infections**: The alteration in gut microbiota can lead to an overgrowth of pathogenic bacteria, increasing the risk of infections, particularly in immunocompromised patients. For instance, the loss of beneficial bacteria such as *Lactobacillus* can predispose patients to *Clostridioides difficile* infections[6].
- **Gastrointestinal Toxicities**: Chemotherapy-induced mucositis and diarrhea are common side effects that can be exacerbated by dysbiosis. The disruption of the gut barrier function allows for bacterial translocation, leading to systemic inflammation and increased toxicity [8].
- **Altered Immune Responses**: Dysbiosis can impair the immune system's ability to respond effectively to both the malignancy and infections. A decrease in microbial diversity is associated with reduced regulatory T-cell (Treg) function, which is crucial for maintaining immune tolerance and preventing excessive inflammation [13]

Mechanisms Linking Gut Microbiota to MM Progression

Microbial Metabolites and Tumor Microenvironment

The gut microbiome produces various metabolites that can influence tumor progression and immune responses (Table 2). Key metabolites include:

Table 2

Metabolite	Source Bacteria	Role in MM
Butyrate	*Faecalibacterium*	Suppresses pro-inflammatory cytokines (e.g., IL-6), inhibits MM cell growth
Ammonia	*Klebsiella*	Fuels tumor nitrogen metabolism, promoting MM cell proliferation
d	*Clostridium*	Induces apoptosis in MM cells, potentially reducing tumor burden

Nitrogen-Recycling Bacteria:

In MM patients, an increase in nitrogen-recycling bacteria such as Klebsiella and Streptococcus has been observed. These bacteria metabolize urea into ammonia, which can provide nitrogen for protein synthesis in malignant cells, thereby promoting tumor growth [3].

Preventive Measures and Microbiota-Based Interventions

Given the significant impact of chemotherapy-induced dysbiosis on MM treatment outcomes, there is growing interest in developing strategies to preserve or restore gut microbiota balance. These strategies include dietary interventions, probiotics, prebiotics, and fecal microbiota transplantation (FMT).

Dietary Interventions

Diet plays a crucial role in shaping the gut microbiota. A diet rich in fiber, fruits, and vegetables has been shown to promote the growth of beneficial bacteria, such as *Eubacterium rectale* and *Faecalibacterium prausnitzii*, which produce SCFAs and have anti-inflammatory effects. Conversely, a diet high in processed meats and low in fiber has been associated with an increased risk of MM and poor treatment outcomes [1,2,12].

Several studies have demonstrated that dietary interventions can improve gut microbiota composition and reduce chemotherapy-induced toxicity. For example, a plant-based diet has been shown to increase SCFA levels and reduce inflammation in MM patients. Additionally, the consumption of whole grains, which have a low glycemic index, has been linked to a reduced risk of MM progression [1,2,12].

Probiotics and Prebiotics

Probiotics, which are live microorganisms that confer health benefits when consumed, have been proposed as a potential strategy to mitigate chemotherapy-induced dysbiosis. Several studies have shown that probiotics, such as *Lactobacillus* and *Bifidobacterium* species, can reduce gastrointestinal toxicity and improve treatment outcomes in cancer patients [1,5,11] Prebiotics, which are non-digestible food components that promote the growth of beneficial bacteria, have also been investigated as a means to support gut microbiota health. For example, the consumption of prebiotic fibers, such as inulin and fructooligosaccharides, has been shown to increase SCFA production and reduce inflammation in MM patients [1,5,11]

Fecal Microbiota Transplantation (FMT)

Fecal microbiota transplantation (FMT), which involves the transfer of fecal material from a healthy donor to a patient, has emerged as a promising intervention for restoring gut microbiota balance in MM patients. FMT has been shown to improve treatment outcomes and reduce the risk of infections in patients undergoing HSCT. Additionally, FMT has been used to treat recurrent Clostridium difficile infections, which are common in MM patients receiving antibiotics [1,5,10]. However, the use of FMT in MM patients is still in its early stages, and further research is needed to determine its safety and efficacy. Potential risks of FMT include the transmission of infectious agents and the development of adverse immune reactions [1,5,10].

Interventions to Restore Gut Microbiota

Several strategies have been proposed to restore gut microbiota balance in MM patients undergoing chemotherapy (Table 3):

Table 3

Strategy	Mechanism	Clinical Outcomes	References
Probiotics	Restore beneficial bacteria (e.g., *Lactobacillus*, *Bifidobacterium*)	↓ Chemotherapy-induced diarrhea, improved gut health	11
Fecal Microbiota Transplantation (FMT)	Replenish microbial diversity	Improved ASCT outcomes, ↓ infections	10
High-Fiber Diet	↑ SCFA production (butyrate)	Enhanced anti-tumor immunity, improved gut barrier function	12

Probiotics in Hematopoietic Stem Cell Transplantation and MM Treatment

Probiotics have gained attention as a potential therapeutic strategy to mitigate the adverse effects of chemotherapy and improve gut health in patients with multiple myeloma, particularly those undergoing hematopoietic stem cell transplantation (HSCT). According to Gallagher et al. [7], probiotics can play a significant role in restoring gut microbiota balance, enhancing immune function, and reducing gastrointestinal toxicity associated with chemotherapy.

- **Mechanisms of Action:** Probiotics, such as Lactobacillus and Bifidobacterium species, can help restore the diversity of gut microbiota that is often disrupted by chemotherapy. They exert beneficial effects by:

- **Enhancing Gut Barrier Function:** Probiotics can strengthen the intestinal barrier, reducing gut permeability and preventing bacterial translocation, which is crucial for immunocompromised patients [7].
- **Modulating Immune Responses:** Probiotics can enhance the immune response by promoting the production of anti-inflammatory cytokines and increasing the activity of immune cells, which is particularly important for patients undergoing HSCT who are at high risk for infections [7].
- **Reducing Gastrointestinal Toxicity:** Clinical studies have shown that probiotics can significantly reduce the incidence and severity of chemotherapy-induced gastrointestinal side effects, such as mucositis and diarrhea, thereby improving the overall quality of life for patients [7].
- **Clinical Evidence:** Several clinical trials have demonstrated the efficacy of probiotics in reducing complications associated with HSCT. For instance, a study involving MM patients undergoing HSCT found that those who received a specific probiotic formulation experienced a lower incidence of mucositis and gastrointestinal infections compared to those who did not receive probiotics [7]. This suggests that probiotics may serve as a valuable adjunctive therapy in the management of MM patients undergoing intensive treatment regimens.
- **Recommendations for Use:** While the use of probiotics appears promising, it is essential to consider the specific strains and dosages that are most effective. Future research should focus on identifying the optimal probiotic formulations that can be integrated into standard care for MM patients, particularly those undergoing HSCT.

Clinical Trials in MM

Recent clinical trials have explored the efficacy of various interventions aimed at restoring gut microbiota in MM patients (Table 4):

Table 4

Trial	Intervention	Sample Size	Key Findings	Refrences
NCT04559884	VSL#3 probiotic	45 MM patients	↓ Mucositis severity post-ASCT	7
NCT03922035	FMT + chemotherapy	12 MM patients	Restored *Blautia*, improved progression-free survival (PFS)	10

Clinical Implications and Future Directions

The interplay between chemotherapy and gut microbiota in MM has significant clinical implications. Understanding the role of gut microbiota in treatment responses can lead to personalized therapeutic strategies.

- **Biomarkers**: Gut microbiota signatures, such as low abundance of *Blautia* or *Faecalibacterium*, may serve as predictive biomarkers for treatment outcomes in MM patients undergoing chemotherapy. Identifying these biomarkers could help tailor treatment plans and improve patient management [6].
- **Personalized Therapy**: The concept of pharmacomicrobiomics, which involves tailoring chemotherapy regimens based on individual microbiota profiles, is an emerging area of research. For instance, patients with a higher baseline abundance of beneficial bacteria may tolerate chemotherapy better and experience fewer side effects [13].
- **Integration of Nutritional Interventions**: Future studies should focus on integrating dietary modifications, such as high-fiber diets and specific probiotic supplementation, into standard MM treatment protocols. This approach could enhance gut health, improve treatment tolerance, and potentially lead to better clinical outcomes.
- **Longitudinal Studies**: More longitudinal studies are needed to assess the long-term effects of chemotherapy on gut microbiota and the subsequent impact on MM progression and patient quality of life. Understanding these dynamics will be crucial for developing effective interventions.

Key Findings:

Gut Microbiota and MM Progression: Multiple studies highlight the role of gut microbiota in MM progression, with dysbiosis promoting disease and beneficial bacteria (e.g., SCFA producers) improving outcomes.

Chemotherapy-Induced Dysbiosis: Chemotherapy disrupts gut microbiota, reducing microbial diversity and increasing pathogenic bacteria, which can negatively impact treatment efficacy and patient quality of life.

Microbiota-Based Interventions: Dietary interventions, probiotics, and FMT show promise in restoring gut microbiota balance and improving MM treatment outcomes.

Inflammation and Immune Modulation: Gut microbiota influences MM progression through immune modulation, particularly via IL-17 and Th17 cells, suggesting potential therapeutic targets (Tabel 5).

Table 5

Study Focus	Key Findings	Methodology	Implications for MM Treatment	Keywords	Reference
Gut Microbiota and Amino Acid Metabolism in MM	Gut microbiota influences MM progression through amino acid metabolism, particularly glutamine and SCFAs. Dysbiosis promotes MM progression, while SCFA-producing bacteria (e.g., *Eubacterium rectale*) improve outcomes.	Review of literature on gut microbiota, amino acid metabolism, and MM.	Targeting gut microbiota (e.g., FMT, probiotics) may improve MM treatment outcomes.	Gut microbiota, amino acids, MM, SCFAs	1
Causal Associations Between Gut Microbiota and MM	*Eubacterium ruminantium* group increases MM risk, while *Dorea*, *Coprococcus1*, and *RuminococcaceaeUCG014* reduce risk.	Two-sample Mendelian randomization analysis using GWAS data.	Specific gut microbiota may serve as biomarkers for MM risk and potential therapeutic targets.	Gut microbiota, MM, Mendelian randomization	2
Gut Microbiota Alterations in MM Progression	MM patients exhibit reduced microbial diversity and increased pathogenic bacteria (e.g., *Klebsiella pneumoniae*). SCFA-producing bacteria (e.g., *Clostridium butyricum*) are reduced, promoting disease progression.	Metagenomic sequencing and qPCR analysis of fecal samples from MM patients.	Dysbiosis in MM patients may contribute to disease progression and poor treatment outcomes.	Gut microbiota, MM progression, SCFAs	3
Microbiota-Driven Inflammation in MM	Gut microbiota promotes MM progression by driving IL-17-producing cells and eosinophils. *Prevotella heparinolytica* enhances Th17 cell migration to the bone marrow, contributing to MM progression.	In vivo studies using MM mouse models and microbiota analysis.	Targeting microbiota-driven inflammation (e.g., IL-17 inhibition) may slow MM progression.	Gut microbiota, IL-17, MM progression	4
Gut Microbiota and Minimal Residual Disease (MRD) in MM	Higher abundance of butyrate-producing bacteria (e.g., *Eubacterium hallii*) is associated with MRD negativity and improved treatment outcomes.	Analysis of fecal microbiota in MM patients undergoing treatment.	Butyrate-producing bacteria may enhance treatment efficacy and reduce relapse risk in MM.	Gut microbiota, MRD, butyrate, MM	5, 6

Appendix

A. Summary of Key Findings

- **Chemotherapy Agents**: Specific agents like melphalan and bortezomib significantly alter gut microbiota, leading to dysbiosis and increased risk of infections and gastrointestinal toxicities.
- **Mechanisms of Dysbiosis**: Dysbiosis can impair immune responses and promote tumor progression through microbial metabolites and nitrogen-recycling bacteria.
- **Preventive Strategies**: Probiotics, dietary interventions, and fecal microbiota transplantation show promise in restoring gut health and improving treatment outcomes.

B. Future Research Directions

- **Longitudinal Studies**: More studies are needed to understand the long-term effects of chemotherapy on gut microbiota and their implications for MM progression.
- **Personalized Medicine**: Research should focus on integrating microbiome analysis into treatment planning to tailor therapies based on individual microbiota profiles.
- **Nutritional Interventions**: Investigating the impact of specific dietary patterns on gut health and treatment outcomes in MM patients.

CONCLUSION

Chemotherapy for multiple myeloma (MM) can harm the gut microbiome, leading to a condition called dysbiosis. This imbalance can cause problems like infections, stomach issues, and weaker immune responses, which can make treatment less effective and reduce the quality of life for patients. However, new approaches like probiotics, fecal microbiota transplantation (FMT), and special diets show promise in fixing these issues and improving treatment results.

As we learn more about how the gut microbiome affects health and disease, it's clear that we need to consider it when treating MM. By including microbiome health in personalized treatment plans, we can make chemotherapy work better and help patients feel better overall. This approach could lead to better care and outcomes for people with multiple myeloma.

As stated in our earlier work on early diagnostics of MM, Early diagnosis of multiple myeloma significantly improves clinical outcomes since therapeutic intervention may be instituted much earlier before the occurrence of irreversible organ damage [14]. This diagnostic advantage creates an essential window of opportunity not only for initiating modern chemotherapeutic or immunotherapeutic regimens, but also for integrating microbiome-preserving strategies from the outset.

Thus, the synergy between early, precise diagnosis and microbiome-conscious supportive care offers a powerful avenue to optimize MM management. Incorporating gut health into personalized treatment plans from the earliest stages could not only enhance treatment efficacy but also reduce toxicity, prevent complications, and ultimately improve the overall quality of life and survival in MM patients.

REFERENCES

1. Yang, Q., Wei, Y., Zhu, Y., Guo, J., Zhang, J., He, Y., Li, X., Liu, J., & Zhou, W. (2023). The Interaction between Gut Microbiota and Host Amino Acids Metabolism in Multiple Myeloma. Cancers, 15(7), 1942. https://doi.org/10.3390/cancers15071942
2. Zhang, C.-Y., Zhang, D., Sun, W.-R., Tang, H.-L., Tian, B., Hu, L.-H., Hu, W.-Y., Gao, Y.-Y., Li, M.-Y., Xiao, W.-T., Gao, S., & Gao, G.-X. (2024). Causal associations between the gut microbiota and multiple myeloma: a two-sample Mendelian randomization study. Frontiers in Nutrition, 11, 14001114. https://doi.org/10.3389/fnut.2024.1400116
3. Jian, X., Zhu, Y., Ouyang, J., Wang, Y., Lei, Q., Xia, J., Guan, Y., Zhang, J., Guo, J., He, Y., & Zhou, W. (2020). Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria. Microbiome, 8(1), 74. https://doi.org/10.1186/s40168-020-00854-5
4. Calcinotto, A., Brevi, A., Chesi, M., Ferrarese, R., Garcia Perez, L., Grioni, M., Kumar, S., Garbitt, V. M., Sharik, M. E., Henderson, K. J., Tonon, G., & Ghobrial, I. M. (2018). Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nature Communications, 9(1), 4832. https://doi.org/10.1038/s41467-018-07305-8
5. Pianko, M. J., Devlin, S. M., Littmann, E. R., Chansakul, A., Mastery, D., Salcedo, M., Fontana, E., Ling, L., Tavitian, E., Slingerland, J. B., & Peled, J. U. (2019). Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition. Blood Advances, 3(14), 2040–2044. https://doi.org/10.1182/bloodadvances.2019022276
6. D'Angelo C, Sudakaran S, Asimakopoulos F, et al. Perturbation of the Gut Microbiome and Association with Outcomes Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Leuk Lymphoma. 2023;64(1):87–97. https://doi.org/10.1080/10428194.2022.2131410
7. Gallagher K, et al. Probiotics in Hematopoietic Stem Cell Transplantation: A Review of the Literature. Blood Advances. 2022;6(12):3924-3935.
8. Zhou L, et al. The Impact of Bortezomib on Gut Microbiota in Multiple Myeloma Patients. Frontiers in Immunology. 2021;12:678123.
9. Jasinski M, Bilinski J, Basak GW. The Role of the Gut Microbiome in Pathogenesis,

Biology, and Treatment of Plasma Cell Dyscrasias. Frontiers in Oncology. 2021;11:741376. https://doi.org/10.3389/fonc.2021.741376

10. Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal Microbiota Transplant Promotes Response in Immunotherapy-Refractory Melanoma Patients. Science. 2021;371(6529):602–609. https://doi.org/10.1126/science.abb5920.
11. Alkharabsheh O, Sidiqi MH, Aljama MA, Gertz MA, Frankel AE. The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors. Acta Haematologica. 2020;143:118–123. https://doi.org/10.1159/000500976.
12. Kanellos PT, Baxevanis GK, Tentolouris A, Gavriatopoulou M, Ntanasis-Stathopoulos I. The Role of Nutrition and Gut Microbiome in the Progression of Multiple Myeloma and Its Precursor Disease. Frontiers in Oncology. 2024;14:1461128. https://doi.org/10.3389/fonc.2024.1461128.
13. Henig I, Yehudai-Ofir D, Zuckerman T. The clinical role of the gut microbiome and fecal microbiota transplantation in allogeneic stem cell transplantation. Haematologica 2021;106(4):933-946; https://doi.org/10.3324/haematol.2020.247395.
14. J.A. Kholmatov1,3, Sharodiya Das2, Sh.B. Kakhkharova1,3, Shuaib Alam4. (2025). EARLY DIAGNOSTICS OF ONCOLOGICAL DISEASES IN THE EXAMPLE OF MULTIPLE MYELOMA: MODERN TECHNOLOGIES [Data set]. Zenodo. https://doi.org/10.5281/zenodo.15042835